Analysts Set Immune Design Corp (IMDZ) Price Target at $16.00

Immune Design Corp (NASDAQ:IMDZ) has been given a consensus recommendation of “Hold” by the seven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $16.00.

Several research firms have recently issued reports on IMDZ. Zacks Investment Research raised Immune Design from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Monday, November 6th. ValuEngine cut Immune Design from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Finally, Cowen reissued a “buy” rating on shares of Immune Design in a research note on Monday, December 11th.

Immune Design (NASDAQ IMDZ) traded down $0.10 during trading hours on Friday, hitting $3.35. The stock had a trading volume of 433,235 shares, compared to its average volume of 662,787. Immune Design has a 12 month low of $2.90 and a 12 month high of $13.05. The company has a market capitalization of $160.99, a PE ratio of -1.57 and a beta of 2.03.

In other news, CEO Carlos V. Paya sold 7,970 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.17, for a total transaction of $33,234.90. Following the completion of the sale, the chief executive officer now directly owns 114,560 shares of the company’s stock, valued at $477,715.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Leo Guthart bought 20,000 shares of Immune Design stock in a transaction dated Monday, January 8th. The shares were bought at an average cost of $3.90 per share, with a total value of $78,000.00. The disclosure for this purchase can be found here. Insiders have sold 13,959 shares of company stock valued at $58,209 in the last ninety days. Company insiders own 20.70% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its stake in Immune Design by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 1,600 shares in the last quarter. California State Teachers Retirement System lifted its stake in Immune Design by 8.3% in the 2nd quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 2,300 shares in the last quarter. Teachers Advisors LLC lifted its stake in Immune Design by 23.0% in the 2nd quarter. Teachers Advisors LLC now owns 27,691 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 5,181 shares in the last quarter. Rhumbline Advisers lifted its stake in Immune Design by 53.9% in the 2nd quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 6,896 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Immune Design by 95.1% during the 2nd quarter. New York State Common Retirement Fund now owns 20,100 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 9,799 shares in the last quarter. 25.16% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/18/analysts-set-immune-design-corp-imdz-price-target-at-16-00.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply